Efficacy, Safety and Long-term Prognosis of Imatinib in Patients Newly Diagnosed With Chronic Myelogenous Leukemia (Chronic Phase)

• Status: Completed
• Trial end date: 2007-06-01
• Target enrollment: 0
• Participant gender: All

Summary

This study will assess the safety and efficacy of imatinib in newly enrolled previously untreated patients with chronic phase CML.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Novartis
• Treatments: Imatinib Mesylate

Criteria

Inclusion Criteria:

• Diagnosed as Chronic Myelogenous Leukemia in Chronic Phase

• Previously untreated with Interferon-alpha

• Performance status is normal or capable of only limited self-care

Exclusion Criteria:

• Patients who are pregnant or possibly pregnant

• Significant hepatic diseases

• Chronic Myelogenous Leukemia in advanced phase

Other protocol-defined inclusion/exclusion criteria may apply.